Director, Business Development & Acquisitions - Aesthetics
AbbVie
Summary
The Business Development & Acquisitions function drives the advancement of AbbVie's R&D pipeline and commercial business by assessing and executing key strategic transactions. Example transaction types include in-licensing, out-licensing, co-development / co-promotion, collaboration, and option deals, as well as divestiture / carve-outs and mergers & acquisitions. The Director, Business Development & Acquisitions of Aesthetics, supports those efforts through development of analytical assessments to determine opportunity viability, communication of findings to senior management and participation in terms and contract negotiations.
Job description
Responsibilities
- Supports the achievement of overall business development objectives, strategies and tactics for growth of AbbVie's pharmaceutical and aesthetics businesses.
- Partners with Search & Evaluation and Global Commercial Development team members as well as key Therapeutic Area subject matter experts to efficiently identify and advance opportunities.
- Works constructively with key stakeholders and cross-functional teams to conduct timely initial technical assessments and full due diligence of prioritized opportunities, with specific responsibility for business and financial diligence.
- Presents business components of key opportunities to therapeutic area and enterprise governance bodies concisely, demonstrating strong executive presence and mastery of both strategic rationale and detailed findings for individual opportunity, to enable effective decision-making.
- Leads deal negotiations, including collaboration with Transactions Legal, to secure both internal and partner alignment on all key terms from initial discussions of economics through contract execution.
- Represents BD&A, as needed, during key internal planning processes (e.g., Business Development Strategy, Long Range Plan) and ad hoc strategic projects as requested by Executive Leadership Team.
- Participates in external partnering meetings and conferences to build individual network and advance AbbVie's position as a biopharma "partner of choice."
- Monitors global and domestic industry and transaction trends and activities.
- This role will be focused on the Obesity and Aesthetics Therapeutic Areas.
- This role will require domestic and international travel - estimated 10-20%.
- This role requires at least three (3) days onsite, Tuesday - Thursday, in the respective AbbVie office(s).
Requirements
- Bachelor's Degree Required
- Advanced degree (PhD, PharmD, MBA) preferred
- 7+ years of experience in pharmaceutical / biotech industry required
- Licensing and acquisitions experience strongly preferred
- Marketing, consulting, strategy and/or operational experience also acceptable
- International or cross-border experience a plus
- Strong grasp of the fundamentals of pharmaceutical drug discovery, development, and commercialization
- Clear understanding of financial analysis and corporate finance from critical reading of financial statements and annual reports to generation and validation of forecast and valuation models
- Strategic and critical thinker, with ability to identify and pressure-test key sensitivities in business cases and diligence team findings
- Practical drive for results, with ability to identify and achieve the right level of granularity to balance speed of execution and facilitate optimal decision-making by executive management
- Excellent communication and interpersonal skills, including experience leading cross-functional teams and successfully interacting with executive-level management
Benefits
- Paid time off
- Medical, Dental & Vision
- 401(k)
- Long-term incentive programs
Company overview
AbbVie is a global biopharmaceutical company that discovers, develops, and markets advanced therapies for some of the world's most complex and serious diseases. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has established itself as a leader in immunology, oncology, neuroscience, eye care, and virology. The company's flagship product, Humira (adalimumab), was one of the world's top-selling drugs for treating autoimmune conditions like rheumatoid arthritis and Crohn's disease. AbbVie maintains a robust pipeline of innovative medicines and has expanded its portfolio through strategic acquisitions, including Allergan in 2020. With research facilities across the United States and globally, AbbVie focuses on advancing science to improve patient outcomes while maintaining strong commercial operations worldwide. The company operates with a patient-centric approach and invests significantly in research and development to address unmet medical needs across multiple therapeutic areas.